Lilly VP: India Can Be Global Pharma Innovation Hub with Policy Reforms

• Patrik Jonsson, Executive VP at Eli Lilly International, states India can become a global pharmaceutical innovation hub by strengthening policy frameworks and aligning with global standards.
• Jonsson emphasizes India's strong scientific talent but highlights the need for more predictable and innovation-friendly regulations to unlock its full potential.
• He stresses the importance of stronger intellectual property protection and regulatory data protection, noting that compulsory licensing is a concern and regulatory data protection would attract global investment.
• Lilly is deepening its presence in India with a $1 billion manufacturing investment and expanded operations in Hyderabad and Bengaluru, also exploring AI-led drug discovery with Nvidia.
• Despite India's promise, challenges like regulation, pricing, and generic competition persist, even as companies like Lilly drive innovation in areas such as diabetes and obesity treatment.